Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Psychedelics and novel therapeutics

TL;DR — Psilocybin-assisted therapy has produced rapid, sometimes sustained symptom reductions in several randomized depression trials, but expectancy, functional unblinding, intensive psychological support, exclusion of complex patients, and small samples make conventional effect estimates hard to interpret. Against escitalopram, psilocybin did not significantly improve the prespecified primary endpoint; uncorrected secondary outcomes favored psilocybin (Carhart-Harris 2021, PMID 33852780). A 233-participant TRD trial found 25 mg superior to 1 mg at week 3, with adverse events including headache, nausea, dizziness, and suicidal ideation/behavior in all dose groups (Goodwin 2022, PMID 36322843). Meta-analyses find benefit but inherit trial limitations (Haikazian 2023, PMID 37844352; Metaxa 2024, PMID 38692686). These are treatment packages—drug, preparation, session, support, and integration—not pills alone.

Trial map

Trial Population/comparator Main finding
Davis 2021 MDD; immediate vs delayed treatment large short-term symptom reduction (PMID 33146667)
Carhart-Harris 2021 psilocybin vs escitalopram primary endpoint not significantly different (PMID 33852780)
Goodwin 2022 TRD; 25 mg/10 mg/1 mg 25 mg superior at week 3 (PMID 36322843)
Raison 2023 MDD; 25 mg vs niacin placebo significant day-43 symptom benefit (PMID 37651119)
Feifel 2026 TRD; single intranasal mebufotenin 12 mg/8 mg vs 0.3 mg day-29 MADRS difference −5.3 for 12 mg (PMID 42931733; NCT05870540)

NHS feasibility evidence

A public-healthcare feasibility trial compared psilocybin plus psychological support with placebo plus the same support. Recruitment, retention and outcome-measure variance were the primary feasibility objectives; symptom differences were preliminary efficacy estimates. The full text reports failed participant blinding and minimal placebo improvement, so the trial supports feasibility while leaving expectancy and the drug–support contribution unresolved (Rucker 2026, PMID 42562964). The EU Clinical Trials Register posted results on 26 September 2026 for EudraCT 2018-003573-97. That results page was re-opened on 2026-10-22: version 1 remained the current version, with the same publication date. The ClinicalTrials.gov record still has no results section (NCT04959253).

Short-acting psychedelics: intranasal mebufotenin

Mebufotenin (5-MeO-DMT) is a 5-HT1A and 5-HT2A agonist whose psychedelic experience is brief. That brevity is the point of development: psilocybin needs prolonged in-clinic monitoring. A phase 2b double-blind trial ran at 38 sites in Australia, Europe and the US. It randomized adults with TRD, defined as nonresponse to 2–5 antidepressant trials in the current episode, to one intranasal dose of mebufotenin benzoate: 12 mg (n = 73), 8 mg (n = 46) or a 0.3-mg low-dose comparator (n = 74). Every arm received psychological support. The primary endpoint, day-29 MADRS change for 12 mg versus 0.3 mg, was −11.1 versus −5.5 points (mean difference −5.3, 95% CI −8.9 to −1.8; P = .003). The 8-mg difference was −6.2 (95% CI −10.2 to −2.1). Day-29 response was 34% (12 mg), 35% (8 mg) and 12% (0.3 mg); remission was 18%, 26% and 8%. Treatment-emergent adverse events occurred in 85%, 76% and 73%, and 99.7% of events were mild or moderate. Discharge readiness within 2 hours was 78% (12 mg) and 85% (8 mg) (Feifel 2026, PMID 42931733). The ClinicalTrials.gov results posted on 2026-09-10 report the same least-squares difference (−5.3; 95% CI −8.9 to −1.8; P = 0.0033) for 196 enrolled participants (NCT05870540).

How to read this: the sponsor (Beckley Psytech/AtaiBeckley) funded the trial and employed several authors. Follow-up was 8 weeks after a single dose. The 8-mg arm was smaller than the other two. The full text is embargoed in PMC, so this sweep read only the abstract, the key points and the registry results, not the blinding assessment or the 18 secondary endpoints. A 0.3-mg comparator is unlikely to mask a perceptible psychedelic experience. The blinding problem below therefore applies here too, until the trial's blinding data have been read.

The blinding problem

Psychedelic effects make allocation readily guessable. Expectancy can influence participants, therapists, raters, co-interventions, and attrition. Low-dose psychedelic controls may not preserve blinding; niacin creates bodily sensation but not comparable experience.

Design improvement Purpose
Assess treatment guesses repeatedly quantify functional unblinding
Independent masked raters reduce observer expectancy
Credible active control narrow experiential differences
Standardize support isolate package components
Report expectancy model moderation
Long follow-up distinguish transient response from durable remission

Safety and generalizability

Controlled trials exclude many people at risk for psychosis, mania, unstable medical illness, or severe substance problems. Systematic review of classic-psychedelic trials found acute adverse events generally transient in screened settings but emphasized limited detection of rare and long-term harms (Hinkle 2024, PMID 39230883).

Potential concerns include panic, hypertension, prolonged distress, mania or psychosis in susceptible people, exploitation or boundary violations in altered states, and post-session suicidality. Safety of supervised research does not transfer automatically to unsupervised use.

Novel non-psychedelic agents

Agent Mechanism frame Evidence
Dextromethorphan–bupropion NMDA/sigma-1 plus metabolic boosting phase 3 MDD efficacy (Iosifescu 2022, PMID 35649167)
Zuranolone neuroactive-steroid GABA-A modulation phase 3 MDD trial positive; effect durability and positioning debated (Clayton 2023, PMID 37132201)
Anti-inflammatory strategies biomarker-enriched immunomodulation experimental; subgroup definition unresolved
Hydroxynorketamine ketamine metabolite/plasticity phase 2 recruiting (NCT06511908)

Regulatory evidence standard

An approval decision must separate acute efficacy from the infrastructure required for safe delivery. For psychedelics, therapist training, session duration, emergency procedures, reporting of misconduct, and long-term follow-up are part of the intervention's safety case.

ClinicalTrials.gov v2 records re-fetched on 2026-10-29 show phase 3 CYB003 still recruiting, last update posted 2026-10-27 (NCT06793397). The music- versus mindfulness-centered psilocybin-support study is still not yet recruiting (NCT07373535). GM-2505 is still a completed phase 2 study with no posted registry results, last update posted 2026-10-19 (NCT06236880).

Novel-therapy evidence deepening

Novel mechanism does not remove conventional trial problems. Psilocybin studies add functional unblinding and therapist/context effects; neurosteroid studies add short-course durability questions.

Platform Signal Central controversy
Psilocybin-assisted therapy Controlled trials show rapid, sometimes sustained symptom improvement Expectancy, therapist time, active placebo choice, and multiplicity can enlarge estimates
Psilocybin vs escitalopram Primary endpoint was not significantly different; several secondary outcomes favored psilocybin Secondary outcomes were not multiplicity-adjusted and allocation was conspicuous
COMP360 in TRD A 25-mg dose improved symptoms at 3 weeks Serious adverse events, durability, and retreatment remain important
Zuranolone Short oral courses can produce early symptom separation in some phase 3 trials Not every MDD trial met its primary endpoint; durability after day 14 is central
Brexanolone Randomized postpartum-depression evidence supports a neurosteroid mechanism IV monitoring burden and perinatal specificity limit generalization
Gepirone ER Serotonergic receptor-selective strategy with acute MDD trials Comparative effectiveness and acceptability versus established agents remain uncertain

Claims about “psychedelic efficacy” should keep drug, preparation, psychotherapy/support, expectancy, and post-session integration analytically separable.

Additional live-search evidence ledger

The records below were added after full PubMed E-utilities retrieval on 2026-08-30. The ledger states the evidentiary role of each record and preserves the design limitation that should travel with its citation.

  • Erritzoe D 2024 — Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. Observational post-trial follow-up; attrition and subsequent treatment prevent treating six-month differences as a preserved randomized contrast. (Erritzoe D 2024, PMID 39764567)

  • Szigeti B 2024 — Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Szigeti B 2024, PMID 38247730)

  • Barba T 2022 — Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Barba T 2022, PMID 36065128)

  • Orsini DK 2026 — Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Orsini DK 2026, PMID 41984443)

  • Hieronymus F 2025 — Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Hieronymus F 2025, PMID 40736734)

  • Fonzo GA 2025 — Psilocybin: From Psychiatric Pariah to Perceived Panacea. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Fonzo GA 2025, PMID 39741437)

  • Hovmand OR 2023 — Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Hovmand OR 2023, PMID 37403379)

  • Højlund M 2025 — Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Højlund M 2025, PMID 41205366)

  • Barrett FS 2018 — Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Barrett FS 2018, PMID 28401522)

  • Li JR 2025 — The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Li JR 2025, PMID 39389119)

  • Galvão-Coelho NL 2021 — Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Galvão-Coelho NL 2021, PMID 33427944)

  • Kato M 2026 — Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Kato M 2026, PMID 41251319)

  • Parikh SV 2024 — Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Parikh SV 2024, PMID 37875578)

  • Deligiannidis KM 2021 — Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Deligiannidis KM 2021, PMID 34190962)

  • Clayton AH 2023 — Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Clayton AH 2023, PMID 36811520)

  • Deligiannidis KM 2023 — Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Deligiannidis KM 2023, PMID 36724109)

  • Kato M 2023 — Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Kato M 2023, PMID 37252829)

Open questions

  • How large is psilocybin's pharmacologic effect after expectancy and unblinding are measured?
  • Which components of preparation and integration are necessary?
  • What are rates of mania, persistent perceptual symptoms, and suicidality in broad populations (Hinkle 2024, PMID 39230883)?
  • Do repeated or analog compounds improve durability without increasing risk?
  • Do short-acting psychedelics such as intranasal mebufotenin keep their effect beyond 8 weeks and against an experientially matched control (Feifel 2026, PMID 42931733)?

References

  1. Carhart-Harris R, et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 2021. PMID 33852780
  2. Goodwin GM, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine. 2022. PMID 36322843
  3. Davis AK, et al. Psilocybin-Assisted Therapy on MDD. JAMA Psychiatry. 2021. PMID 33146667
  4. Raison CL, et al. Single-Dose Psilocybin Treatment for MDD. JAMA. 2023. PMID 37651119
  5. Haikazian S, et al. Psilocybin-assisted therapy for depression: systematic review and meta-analysis. Psychiatry Research. 2023. PMID 37844352
  6. Metaxa AM, Clarke M. Efficacy of psilocybin for depression. BMJ. 2024. PMID 38692686
  7. Hinkle JT, et al. Adverse Events in Studies of Classic Psychedelics. JAMA Psychiatry. 2024. PMID 39230883
  8. Iosifescu DV, et al. Dextromethorphan-bupropion in MDD. Journal of Clinical Psychiatry. 2022. PMID 35649167
  9. Clayton AH, et al. Zuranolone for Adults With MDD. American Journal of Psychiatry. 2023. PMID 37132201
  10. Erritzoe D, et al. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine. 2024;76:102799. PMID 39764567
  11. Szigeti B, et al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological medicine. 2024;54:1717-1724. PMID 38247730
  12. Barba T, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych open. 2022;8:e163. PMID 36065128
  13. Orsini DK, et al. Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review. JAMA psychiatry. 2026;83:755-769. PMID 41984443
  14. Hieronymus F, et al. Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis. JAMA network open. 2025;8:e2524119. PMID 40736734
  15. Fonzo GA, et al. Psilocybin: From Psychiatric Pariah to Perceived Panacea. The American journal of psychiatry. 2025;182:54-78. PMID 39741437
  16. Hovmand OR, et al. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. Journal of psychopharmacology (Oxford, England). 2023;37:649-659. PMID 37403379
  17. Højlund M, et al. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2025;101:41-55. PMID 41205366
  18. Barrett FS, et al. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Current topics in behavioral neurosciences. 2018;36:393-430. PMID 28401522
  19. Li JR, et al. The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. Journal of affective disorders. 2025;369:421-428. PMID 39389119
  20. Galvão-Coelho NL, et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology. 2021;238:341-354. PMID 33427944
  21. Kato M, et al. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial. Psychiatry and clinical neurosciences. 2026;80:76-86. PMID 41251319
  22. Parikh SV, et al. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024;49:467-475. PMID 37875578
  23. Deligiannidis KM, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA psychiatry. 2021;78:951-959. PMID 34190962
  24. Clayton AH, et al. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. The Journal of clinical psychiatry. 2023;84:22m14445. PMID 36811520
  25. Deligiannidis KM, et al. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression. The Journal of clinical psychiatry. 2023;84:22m14475. PMID 36724109
  26. Kato M, et al. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial. Psychiatry and clinical neurosciences. 2023;77:497-509. PMID 37252829
  27. Rucker JJ, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature Medicine. 2026. PMID 42562964
  28. EU Clinical Trials Register. Results for EudraCT 2018-003573-97. https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003573-97/results, accessed 2026-10-15.
  29. Feifel D, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. 2026. PMID 42931733